title: Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.
authors.affiliation: Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy massimo.federico@unimore.it.
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
authors.affiliation: Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Luminari
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.affiliation: Arcispedale "Santa Maria Nuova" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Merli
authors.affiliation: Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
authors.forename: Emanuela Anna
authors.initials: EA
authors.lastname: Pesce
authors.affiliation: Santa Croce e Carle Hospital, Cuneo, Italy.
authors.forename: Stephane
authors.initials: S
authors.lastname: Chauvie
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Gandolfi
authors.affiliation: Arcispedale "Santa Maria Nuova" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy.
authors.forename: Isabella
authors.initials: I
authors.lastname: Capodanno
authors.affiliation: Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Salati
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.affiliation: Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000079963:Brentuximab Vedotin; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D005720:Gamma Rays / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D009367:Neoplasm Staging; D009503:Neutropenia / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D010865:Pilot Projects; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: ABVD; Hodgkin lymphoma; brentuximab vedotin; early; intermediate; radiotherapy; toxicity